Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya26715ArticlesСтатьиResearch ArticlePrimenenie tsetuksimaba v lechenii ploskokletochnogo raka golovy i sheiПрименение цетуксимаба в лечении плоскоклеточного рака головы и шеиRomanovI SРомановИ СKupchanD ZКупчанД ЗГУ Российский онкологический центр им. Н.Н.Блохина РАМН, Москва15062008102NO2 (2008)ТОМ 10, №2 (2008)374409042020Copyright ©; 2008, Consilium MedicumCopyright ©; 2008, ООО "Консилиум Медикум"2008Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/26715

Рак головы и шеи является широким понятием, к которому относятся опухоли, возникающие на слизистой оболочке различных отделов верхних дыхательно-пищеварительных путей. Наиболее часто встречающиеся локализации: полость рта, гортань, ротоглотка, гортаноглотка и носоглотка. Рак головы и шеи (включая полость рта, глотку, гортань и др.) составляет 5% от всей опухолевой патологии в мире. В 2002 г. отмечено более 500 000 новых случаев рака головы и шеи и 300 000 смертей от него. Плоскоклеточная форма рака составляет более 95% всех форм рака головы и шеи.Почти в 100% случаев рецептор эпидермального фактора роста (РЭФР) экспрессируется плоскоклеточным раком головы и шеи (ПРГШ), и его экспрессия обычно коррелирует со снижением безрецидивной и общей продолжительностями жизни. Таким образом, целью при лечении ПРГШ становится изучение роли рецепторов эпидермального фактора роста в развитии и прогрессии опухоли.

плоскоклеточный ракрак головы и шеихимиотерапияцетуксимабParkin D.M., Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55 (2): 74–108.Grandis J.R., Melhem M.F., Gooding W.E. et al. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90 (11): 824–8.Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958–70.Damjanov N, Meropol N.J. Oncology 2004; 479–503.Merck. Data on file, GERBPK001. Merck KGaA.Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti - epidermal growth factor receptor monoclonal antibodies plus cis - diamminedichloroplat - inum on well established A431 cell xenografts. Cancer Res 1993; 53: 4637–42.Milas L, Fan Z, Andratschke N.H., Ang K.K. Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004; 58: 966–71.Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of dam - age repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166–74.Iro H, Waldfahrer F. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer 1998; 83: 2201–7.Vernham G.A., Crowther J.A. Head and neck carcinoma - stage at presentation. Clin Otolaryngol Allied Sci 1994; 19: 120–4.Vokes E.E., Weichselbaum R.R., Lippman S.M., Hong W.K. Head and neck cancer. N Engl J Med 1993; 328: 184–94.Decker D, Drelichman A, Jacobs J et al. Adjuvant chemotherapy with high dose bolus cis - diamminodichloroplatinum II (CDDP) and 120 hour infusion 5 - fluo - rouracil (5-FU) in stage III and IV squamous cell carcinoma of the head and neck. ASCO annual meeting 1982, Saint Louis: abstr C-757.Decker D, Drelichman A, Jacobs J et al. Adjuvant chemotherapy with cis - diamminodichloroplatinum II and 120 hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neck. Cancer 1983; 51: 1353–5.Ensley J, Jacobs J, Weaver A et al. Initial cis - platinum combination predicting response to radiotherapy in patients with advanced epidermoid cancers of head and neck. ASCO annual meeting 1982, Saint Louis: abstr C-767.Ensley J.F., Jacobs J.R., Weaver A et al. Correlation between response to cisplat - inum - combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984; 54: 811–4.Bourhis J, Amand C, Pignon J-P, on behalf of the MACH-NC Collaborative Group. Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concominant chemoradiotherapy. J Clin Oncol ASCO Annual Meeting Proceeding (Post-Meeting Edition) 2004; 22: Abstract 5505.Cohen E.E., Lingen M.W., Vokes E.E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743–52.Pivot X, Kataja V.V., Jelic S. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow - up of squamous cell carcinoma of the head and neck (SCCHN). Ann Oncol 2005; 16 (Suppl. 1): i62–3.Calais G, Alfonsi M, Bardet E et al. Randomised trial of radiation therapy ver - sus concomitant chemotherapy and radiation therapy for advanced - stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081–6.Huguenin P, Beer K.T., Allal A et al. Concominant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22: 4665–73.Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of multicentric randomized German trial in advanced head - and - neck cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1161–71.Budach V, Stuschke M, Budach W et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil - mitomycin is more effective than dose - escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Random - ized Trial. J Clin Oncol 2005; 23: 1125–35.Wendt T.G., Grabenbauer G.G., Rodel C.M. et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318–24.Bernier J, Cooper J.S. Chemoradiation after surgery for high - risk head and neck cancer patients: how strong is the evidence? Oncologist 2005, 10 (3): 215–24.Bernier J, Bentzen S.M. Altered fractionation and combined radiochemothera - py approaches: pioneering new opportunities in head and neck oncology. Eur J Cancer 2005; 39 (5): 560–71.Nguyen N.P., Moltz C.C., Frank C et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15 (3): 383–8.Machtay M, Moughan J, Trotti A et al. Pre - treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: an RTOG analysis. J Clin Oncol 2006; 24 (S18): Abstract 5500.Robert F, Ezekiel M.P., Spencer S.A. et al. Phase I study of anti - epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19 (13): 3234–43.Bonner J.A., Harari P.M., Giralt J et al. Radiotherapy plus cetuximab for squa - mous - cell carcinoma of the head and neck. N Engl J Med 2006; 354 (6): 567–78.Semrau R, Mueller R.P., Stuetzer H et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: Updated results of a randomised multicentic trial in advanced head - and - neck cancer. Int J Radiat Oncol Biol Phys 2006; [Epub: 4th Feb].Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiother - apy alone with concomitant radiochemotherapy in advanced - stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69–76.Schantz S.P., Harrison L.B., Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Princi - ples and Practice of Oncology.De Vita V.T., Hellman S.A., Rosenberg S.A. (Eds). Lippincott Williams & Wilkins, PA, USA, 2001; 797–860.Jacobs C et al. A phase III randomized study comparing cisplatin and fluo - rouracil as single agents and in combination for advanced squamous cell carci - noma of the head and neck. J Clin Oncol 1992; 10: 257–63.Forastiere A.A. et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous - cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245–51.Clavel M et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521–6.Gibson M.K. et al. Randomized phase III evaluation of cisplatin plus fluo - rouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 3562–7.Vermorken J.B. et al. ASCO 2007 (abstract and oral presentation № 6091.Leon X, Hitt R, Constenla M et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum - based chemotherapy. Clin Oncol (R Coll Radiol) 2005; 17 (6): 418–24.Baselga J et al. J Clin Oncol 2005; 23: 5568–77.Herbst R et al. J Clin Oncol 2005; 23: 5578–87.Vermorken J.B. et al. J Clin Oncol 2007; 25: 2171–7.